Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.58 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19508896 | 0.86 | CHRNB2 (0.44) | EPHX1ACHE | |
| SCHEMBL19508894 | 0.83 | EPHX1 (0.61) | EPHX1ACHE | |
| SCHEMBL11233858 | 0.83 | EPHX1 (0.61) | EPHX1ACHE | |
| SCHEMBL19508891 | 0.82 | EPHX1 (0.66) | EPHX1ACHE | |
| SCHEMBL10252302 | 0.82 | EPHX1 (0.66) | EPHX1ACHE | |
| SCHEMBL10304512 | 0.82 | EPHX1 (0.66) | EPHX1ACHE | |
| SCHEMBL27050907 | 0.82 | EPHX1 (0.66) | EPHX1ACHE | |
| SCHEMBL29161883 | 0.81 | EPHX1 (0.63) | EPHX1ACHE | |
| SCHEMBL16443675 | 0.81 | EPHX1 (0.63) | EPHX1ACHE | |
| SCHEMBL10450986 | 0.80 | EPHX1 (0.62) | EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC | 2018-07-05 | — | — | US | disclosed |
| US-9944654-B2 | Nargenicin compounds and uses thereof as antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | EPHX1 4269/4885ACHE 3357/4885ZDHHC20 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.